137 related articles for article (PubMed ID: 24211539)
1. An in vitro approach to assessing a potential drug interaction between MDMA (ecstasy) and caffeine.
Downey C; Daly F; O'Boyle KM
Toxicol In Vitro; 2014 Mar; 28(2):231-9. PubMed ID: 24211539
[TBL] [Abstract][Full Text] [Related]
2. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
McNamara R; Kerans A; O'Neill B; Harkin A
Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
[TBL] [Abstract][Full Text] [Related]
3. Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug.
Camarasa J; Pubill D; Escubedo E
Brain Res; 2006 Sep; 1111(1):72-82. PubMed ID: 16889759
[TBL] [Abstract][Full Text] [Related]
4. Serotonin transporter expression is not sufficient to confer cytotoxicity to 3,4-methylenedioxymethamphetamine (MDMA) in vitro.
Hayat S; Williams RJ; Rattray M
J Psychopharmacol; 2006 Mar; 20(2):257-63. PubMed ID: 16510483
[TBL] [Abstract][Full Text] [Related]
5. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
6. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity.
Biezonski DK; Meyer JS
J Neurochem; 2010 Feb; 112(4):951-62. PubMed ID: 20002520
[TBL] [Abstract][Full Text] [Related]
7. Caffeine induces a profound and persistent tachycardia in response to MDMA ("Ecstasy") administration.
McNamara R; Maginn M; Harkin A
Eur J Pharmacol; 2007 Jan; 555(2-3):194-8. PubMed ID: 17126829
[TBL] [Abstract][Full Text] [Related]
8. Neurotoxicity mechanisms of thioether ecstasy metabolites.
Capela JP; Macedo C; Branco PS; Ferreira LM; Lobo AM; Fernandes E; Remião F; Bastos ML; Dirnagl U; Meisel A; Carvalho F
Neuroscience; 2007 Jun; 146(4):1743-57. PubMed ID: 17467183
[TBL] [Abstract][Full Text] [Related]
9. Interactions between 3,4-methylenedioxymethamphetamine, methamphetamine, ketamine, and caffeine in human intestinal Caco-2 cells and in oral administration to rats.
Kuwayama K; Inoue H; Kanamori T; Tsujikawa K; Miyaguchi H; Iwata Y; Miyauchi S; Kamo N; Kishi T
Forensic Sci Int; 2007 Aug; 170(2-3):183-8. PubMed ID: 17614227
[TBL] [Abstract][Full Text] [Related]
10. Neurochemical and Neurotoxic Effects of MDMA (Ecstasy) and Caffeine After Chronic Combined Administration in Mice.
Górska AM; Kamińska K; Wawrzczak-Bargieła A; Costa G; Morelli M; Przewłocki R; Kreiner G; Gołembiowska K
Neurotox Res; 2018 Apr; 33(3):532-548. PubMed ID: 29134560
[TBL] [Abstract][Full Text] [Related]
11. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.
Gouzoulis-Mayfrank E; Daumann J
J Psychopharmacol; 2006 Mar; 20(2):188-93. PubMed ID: 16510477
[TBL] [Abstract][Full Text] [Related]
12. Metabolic interactions between ethanol and MDMA in primary cultured rat hepatocytes.
Pontes H; de Pinho PG; Fernandes E; Branco PS; Ferreira LM; Carmo H; Remião F; Carvalho F; Bastos ML
Toxicology; 2010 Apr; 270(2-3):150-7. PubMed ID: 20170704
[TBL] [Abstract][Full Text] [Related]
13. Neurotoxicity of Ecstasy metabolites in rat cortical neurons, and influence of hyperthermia.
Capela JP; Meisel A; Abreu AR; Branco PS; Ferreira LM; Lobo AM; Remião F; Bastos ML; Carvalho F
J Pharmacol Exp Ther; 2006 Jan; 316(1):53-61. PubMed ID: 16183702
[TBL] [Abstract][Full Text] [Related]
14. "Ecstasy"-induced toxicity in SH-SY5Y differentiated cells: role of hyperthermia and metabolites.
Barbosa DJ; Capela JP; Silva R; Ferreira LM; Branco PS; Fernandes E; Bastos ML; Carvalho F
Arch Toxicol; 2014 Feb; 88(2):515-31. PubMed ID: 24177245
[TBL] [Abstract][Full Text] [Related]
15. Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats.
Shioda K; Nisijima K; Yoshino T; Kuboshima K; Iwamura T; Yui K; Kato S
Neurotoxicology; 2008 Nov; 29(6):1030-6. PubMed ID: 18722468
[TBL] [Abstract][Full Text] [Related]
16. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
Parrott AC
J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
[TBL] [Abstract][Full Text] [Related]
17. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
Green AR; Mechan AO; Elliott JM; O'Shea E; Colado MI
Pharmacol Rev; 2003 Sep; 55(3):463-508. PubMed ID: 12869661
[TBL] [Abstract][Full Text] [Related]
18. Effect of 3,4-methylenedioxymethamphetamine ("ecstasy") on body temperature and liver antioxidant status in mice: influence of ambient temperature.
Carvalho M; Carvalho F; Remião F; de Lourdes Pereira M; Pires-das-Neves R; de Lourdes Bastos M
Arch Toxicol; 2002 Apr; 76(3):166-72. PubMed ID: 11967622
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms mediating the ability of caffeine to influence MDMA ('Ecstasy')-induced hyperthermia in rats.
Vanattou-Saïfoudine N; McNamara R; Harkin A
Br J Pharmacol; 2010 Jun; 160(4):860-77. PubMed ID: 20590585
[TBL] [Abstract][Full Text] [Related]
20. MDMA ("ecstasy") abuse as an example of dopamine neuroplasticity.
Schenk S
Neurosci Biobehav Rev; 2011 Apr; 35(5):1203-18. PubMed ID: 21184779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
